176 related articles for article (PubMed ID: 36509068)
1. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
2. Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
Else T; Jonasch E; Iliopoulos O; Beckermann KE; Narayan V; Maughan BL; Oudard S; Maranchie JK; Iversen AB; Goldberg CM; Fu W; Perini RF; Liu Y; Linehan WM; Srinivasan R
Clin Cancer Res; 2024 May; 30(9):1750-1757. PubMed ID: 38393723
[TBL] [Abstract][Full Text] [Related]
3. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
4. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
5. The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
Shepherd STC; Drake WM; Turajlic S
Eur J Cancer; 2023 Mar; 182():15-22. PubMed ID: 36708612
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
7. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract][Full Text] [Related]
8. Neurological applications of belzutifan in von Hippel-Lindau disease.
Zhang Y; Nguyen CC; Zhang NT; Fink NS; John JD; Venkatesh OG; Roe JD; Hoffman SC; Lesniak MS; Wolinsky JP; Horbinski C; Szymaniak BM; Buerki RA; Sosman JA; Shenoy NK; Lukas RV
Neuro Oncol; 2023 May; 25(5):827-838. PubMed ID: 36215167
[TBL] [Abstract][Full Text] [Related]
9. Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.
Takamori H; Yamasaki T; Kitadai R; Minamishima YA; Nakamura E
Cancer Sci; 2023 Apr; 114(4):1208-1217. PubMed ID: 36650918
[TBL] [Abstract][Full Text] [Related]
10. Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.
Iacovelli R; Arduini D; Ciccarese C; Pierconti F; Strusi A; Piro G; Carbone C; Foschi N; Daniele G; Tortora G
Crit Rev Oncol Hematol; 2022 Aug; 176():103750. PubMed ID: 35728738
[TBL] [Abstract][Full Text] [Related]
11. Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience.
Neth BJ; Webb MJ; White J; Uhm JH; Pichurin PN; Sener U
J Neurooncol; 2023 Aug; 164(1):239-247. PubMed ID: 37450072
[TBL] [Abstract][Full Text] [Related]
12. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (VHL) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract][Full Text] [Related]
13. In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.
Tirosh A; El Lakis M; Green P; Nockel P; Patel D; Nilubol N; Gara SK; Keutgen XM; Linehan WM; Kebebew E
J Clin Endocrinol Metab; 2018 Apr; 103(4):1631-1638. PubMed ID: 29294023
[TBL] [Abstract][Full Text] [Related]
14. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated Tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract][Full Text] [Related]
15. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
Petrella BL; Lohi J; Brinckerhoff CE
Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic endocrine microadenomatosis in patients with von Hippel-Lindau disease: characterization by VHL/HIF pathway proteins expression.
Périgny M; Hammel P; Corcos O; Larochelle O; Giraud S; Richard S; Sauvanet A; Belghiti J; Ruszniewski P; Bedossa P; Couvelard A
Am J Surg Pathol; 2009 May; 33(5):739-48. PubMed ID: 19238077
[TBL] [Abstract][Full Text] [Related]
17. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J; Brave MH; Weinstock C; Mehta GU; Bradford D; Gittleman H; Bloomquist EW; Charlab R; Hamed SS; Miller CP; Dorff SE; Chambers WA; Mixter BD; Dinin J; Pierce WF; Ricks TK; Tang S; Donoghue M; Pazdur R; Amiri-Kordestani L; Ibrahim A; Beaver JA
Clin Cancer Res; 2022 Nov; 28(22):4843-4848. PubMed ID: 35727604
[TBL] [Abstract][Full Text] [Related]
18. Belzutifan: a novel therapeutic for the management of von Hippel-Lindau disease and beyond.
Curry L; Soleimani M
Future Oncol; 2024 Apr; ():. PubMed ID: 38639572
[TBL] [Abstract][Full Text] [Related]
19. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
Choi WW; Boland JL; Kalola A; Lin J
Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
[TBL] [Abstract][Full Text] [Related]
20. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
